Loading...
 
Back to the list
Mediterr J Rheumatol 2018;29(4):217-20
Article Links
Management of mycophenolate mofetil-induced acne in patients with Systemic Lupus Erythematosus: report of four cases and review of the literature
Carlo Perricone, Fulvia Ceccarelli, Francesca Romana Spinelli, Simona Truglia, Roberta Priori, Guido Valesini, Fabrizio Conti
Authors Information

Lupus Clinic, Sezione di Reumatologia, Dipartimento di Medicina Interna, Sapienza Università di Roma, Rome, Italy

Keywords: Acne, Mycophenolate mofetil, Skin, Systemic Lupus Erythematosus.
References
  1. Adu D, Cross J, Jayne DR. Treatment of systemic lupus erythematosus with mycophenolate mofetil. Lupus 2001;10(3):203-8. [https://doi.org/10.1191/096120301673517315] [PMID: 11315353]
  2. Chan TM, Li FK, Tang CS, Wong RW, Fang GX, Ji YL, et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N Engl J Med 2000;343(16):1156-62. [https://doi.org/10.1056/NEJM200010193431604] [PMID: 11036121]
  3. Alba P, Karim MY, Hunt BJ. Mycophenolate mofetil as a treatment for autoimmune haemolytic anaemia in patients with systemic lupus erythematosus and antiphospholipid syndrome. Lupus 2003;12:633-5. [https://doi.org/10.1191/0961203303lu419cr] [PMID: 12945724]
  4. Schaffellner S, Jakoby E, Kniepeiss D, Stadlbauer V, Duller D, Iberer F, Tscheliessnigg KH.  Center experience in liver transplantation (LTX): management of dermal side effects caused by sirolimus. Int Immunopharmacol 2005;5(1):137-40. [https://doi.org/10.1016/j.intimp.2004.09.017] [PMID: 15589473]
  5. Hartmann M, Enk A. Mycophenolate mofetil and skin diseases. Lupus 2005;14 Suppl 1:s58-63. [PMID: 15803935]
  6. Apostolou T, Tsagalis G, Koutroubas G, Hadjiconstantinou V, Drakopoulos S. Mycophenolate mofetil and oral ulcerations. Transplantation 2004;77:1911-2. [PMID: 15223919]
  7. Naranjo J, Poniachik J, Cisco D, Contreras J, Oksenberg D, Valera JM, et al. Oral ulcers produced by mycophenolate mofetil in two liver transplant patients. Transplant Proc. 2007 Apr;39(3):612-4. [https://doi.org/10.1016/j.transproceed.2006.12.028] [PMID: 17445557]
  8. Rault R. Mycophenolate-associated onycholysis. Ann Intern Med 2000;133:921-2. [PMID: 11103069]
  9. Semhoun-Ducloux S, Ducloux D, Miguet JP. Mycophenolate mofetilinduced dyshidrotic eczema. Ann Intern Med 2000;132:417. [PMID: 10691595]
  10. Pisoni CN, Obermoser G, Cuadrado MJ, Sanchez FJ, Karim Y, Sepp NT, et al. Skin manifestations of systemic lupus erythematosus refractory to multiple treatment modalities: poor results with mycophenolate mofetil. Clin Exp Rheumatol 2005;23(3):393-6. [PMID: 15971430]
  11. Boehm I, Bieber T. Chilblain lupus erythematosus Hutchinson: successful treatment with mycophenolate mofetil. Arch Dermatol 2001;137(2):235-6. [PMID: 11176709]
  12. Satchell AC, Barnetson RS. Staphylococcal septicaemia complicating treatment of atopic dermatitis with mycophenolate. Br J Dermatol 2000;143:202-3. [PMID: 10886168]
  13. Conti F, Ceccarelli F, Iaiani G, Perricone C, Giordano A, Amori L, et al. Association between Staphylococcus aureus nasal carriage and disease phenotype in patients affected by systemic lupus erythematosus. Arthritis Res Ther 2016 30;18:177. [https://doi.org/10.1186/s13075-016-1079-x]